Europe
-
Merck receives European approval to expand use of Rebif
Merck announced that the European Commission (EC) has approved extension of the indication of Rebif (interferon beta-1a), its treatment for relapsing forms of multiple sclerosis (MS).
Europe | 02 March 2012
-
DOCS continues expansion with four new offices in Europe
ICON announced that its resourcing division, DOCS, has expanded in Europe by opening four new offices: in Milan, Italy; Budapest, Hungary; Brussels, Belgium and Berlin, Germany. This latest expansion brings the total number of DOCS offices in Europe to 22.
Europe | 03 February 2012
-
Life Technologies develops test to detect Europe's deadly E coli
Life Technologies Corporation announced that it has developed a custom test (assay) to accurately detect the E coli bacterium that has killed at least 22 people and affected more than 2,100 worldwide, including four new cases reported in the United S…
Europe | 07 June 2011
-
European Commission approves SUTENT
The European Commission has approved Pfizer 's SUTENT (sunitinib malate) for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumors (NET) with disease progression in adults. Experience with SUTENT as ini…
Europe | 23 February 2011
-
GATC opens 3rd sequencing laboratory in Europe
GATC Biotech opened a third sequencing laboratory in Europe. This will be their second in Germany and will be located in the Life Science Center Dusseldorf (LSC). Through the new facilities, scientists from Northern Germany and adjacent countries…
Europe | 06 January 2011
-
Avandia hit hard by European and US regulators
Expert comment from Datamonitor healthcare analyst Christine Henry: "Although Avandia franchise sales have already declined significantly from a high of US$3.2 billion in 2006 worldwide to US$1.2 billion in 2009, the suspension of sales in Europe …
Europe | 15 October 2010
-
Novartis Granted Pediatric Indication for Hypertension Treatment
The European Commission (EC) has granted Diovan (valsartan) a pediatric indication for the treatment of hypertension in children and adolescents 6-18 years of age. Following the Commission's decision, the pediatric indication needs to be implemented …
Europe | 13 May 2010
-
Nycomed and Merck & Co Announce Commercialization Agreements in Europe and Canada
Nycomed and Merck & Co have entered into a co-promotion agreement for Canada and certain European countries for the commercialization of Daxas (roflumilast), an investigational once-daily tablet for patients with Chronic Obstructive Pulmonary Disease…
Europe | 29 April 2010
-
HalcyGen to begin Marketing Authorization Application in Europe
HalcyGen Pharmaceuticals has announced that preliminary results from its UK-based Pharmacokinetic (PK) study comparing a half-dose of anti-fungal drug Suba-Itraconazole with Sporanox, has shown clinical bioequivalence within EU guidelines. Follow…
Europe | 11 March 2010
-
Actavis Launches High Blood Pressure Drug
Actavis Group has announced the launch of Lercanidipine in five European countries. The drug is mainly used to treat high blood pressure. The company launched the product under its own brand name on day one in the UK and France, where the patents…
Europe | 04 February 2010
